| Drug Type Small molecule drug | 
| Synonyms- | 
| Action inhibitors, antagonists | 
| Mechanism BRAF inhibitors(Serine/threonine-protein kinase B-raf inhibitors), CRAF inhibitors(C-Raf kinase inhibitors), FLT3 inhibitors(Tyrosine-protein kinase receptor FLT3 inhibitors) + [10] | 
| Therapeutic Areas | 
| Active Indication- | 
| Inactive Indication | 
| Originator Organization | 
| Active Organization- | 
| Inactive Organization | 
| License Organization- | 
| Drug Highest PhasePendingPreclinical | 
| First Approval Date- | 
| Regulation- | 
| Molecular FormulaC25H33NO8 | 
| InChIKeyFFYMSFGBEJMSFP-LREBCSMRSA-N | 
| CAS Registry23210-58-4 | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Hepatocellular Carcinoma | Preclinical | Hong Kong  | 20 Dec 2021 | 





